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ABSTRACT
More than half of those born after 1960 will develop cancer 
during their lifetime. Fortunately, owing to improved 
diagnosis and treatment, cure rates have risen steadily over 
the last three decades. With an increased survivorship, more 
will experience adverse effects of cancer therapeutics on the 
heart. As the oncologist’s focus begins to encompass the 
issues of cancer survivorship, awareness of the management 
of cardiac toxicity would be prudent for all physicians looking 
after patients with cancer.
INTRODUCTION
Cancer and heart disease are the two most common causes of 
death in Northern Ireland. As cancer survivorship increases, 
understanding of the links between cancer treatments and 
cardiovascular disease becomes crucial for all medical 
practitioners. As cure rates improve, increasing priority can 
be given to optimising quality of life rather than focusing 
on prevention of cancer recurrence. Patients may view the 
adverse effects of cancer treatment in equal concern with 
the diagnosis of cancer itself, and with the development of 
new anti-cancer therapies, physicians must be vigilant for the 
symptoms and signs of emerging cardiovascular problems.
The last decade has seen an exponential growth in the 
numbers of anti-cancer treatments available, especially 
systemic anti-cancer treatment (SACT) and radiotherapy. 
It is these two anti-cancer therapies that are implicated in 
the emerging field of cardio-oncology, whether the aim of 
cancer treatment is curative or palliative (Table 1). This article 
explores the relationship of these treatments to cardiotoxicity, 
the indicative signs and symptoms and the management 
options available.
OVERVIEW OF ANTI-CANCER THERAPIES
Radiotherapy delivers energy via ionising radiation to 
neoplastic cell DNA in such a way that the resultant damage 
induces cell death preferentially in malignant tissue. 
Approximately 40% of patients diagnosed with cancer receive 
radiotherapy1. Radiotherapy may be delivered using external 
beam radiotherapy (EBRT) (Figure 1), sealed internal sources, 
for example gold seeds for prostate cancer, brachytherapy and 
unsealed internal sources, for example, radioactive iodine 
for thyroid cancer. The key principle of minimising normal 
tissue irradiation whilst providing the optimum dose to the 
cancer target dictates that factors such as tumour histology, 
dimensions and position are used in determining the choice 
of irradiation method. Since the 1960s, treatment of lung and 
breast cancer and lymphoma with thoracic radiotherapy has 
increased cardiovascular morbidity via radiation toxicity2. 
In general radiotherapy techniques which do not deliver 
radiation to the heart do not cause cardiotoxicity.
The mechanism of action of each of SACT agent depends on 
the family and the era that they originate from, with newer 
agents having quite different targets than more established 
treatments. Cytotoxic chemotherapy is the nomenclature used 
to describe drugs such as the anthracyclines (eg. doxorubicin) 
and antimetabolites (eg. 5-fluorouracil) which are generally 
non-specific and which cause apoptosis and cause cell death 
by altering key components of cellular metabolism or by 
directly damaging DNA. 
Hormonal therapies, molecular targeting agents and 
immunotherapies are more specific in their mode of 
action. Their cardiotoxicity risk can occur via a number of 
mechanisms:
1. Direct ‘on-target toxicity’ if the molecular target in the 
TABLE 1: 
Commonly used cardiotoxic anti-cancer treatments
Cancer Treatment Examples
Cytotoxic 
chemotherapy
doxorubicin, epirubicin, 
cyclophosphamide, 5-fluorouracil, 
cisplatin, paclitaxel
Targeted therapies trastuzumab, sunitinib, pazopanib
Hormonal therapies tamoxifen, anastrazole, letrozole, 
goserelin, enzalutamide, 
abiraterone
Radiotherapy breast, lung, mediastinal 
lymphoma and oesophageal 
radiotherapy
4 The Ulster Medical Journal
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).
The Ulster Medical Society grants to all users on the basis of a Creative Commons Attribution-NonCommercial-ShareAlike 
4.0 International Licence the right to alter or build upon the work non-commercially, as long as the author is credited 
and the new creation is licensed under identical terms.
cancer also serves an important role in cardiovascular 
biology (e.g. trastuzumab.)
2. Indirect ‘on-target toxicity’ if the molecular target in the 
cancer is also a modifier of cardiovascular risk leading 
to the accelerated progression of a second disease (e.g. 
GnRH agonists for prostate cancer which increase LDL 
and diabetes risk leading to atherosclerosis and increased 
risk of myocardial infarction.)
3. ‘Off target toxicity’ where the drug appears to inhibit a 
range of molecular targets, not only the principle target 
molecule in the cancer, and inhibition or activation these 
additional pathways imparts cardiovascular risk (e.g. 
sunitinib displays both on-target and off-target toxicity.)
EXAMPLES OF CARDIOTOXIC TREATMENTS
External beam radiotherapy
Lung cancer
Curative intent radiotherapy is offered to patients diagnosed 
with stage I - III non-small cell lung cancer or limited 
stage small cell lung cancer who have a good Performance 
Status3. EBRT is often the treatment of choice for patients 
who decline, or are unsuitable for surgery. Recent progress 
in radiation technology has the potential to revolutionise 
lung cancer treatment, with advances such as stereotactic 
ablative radiotherapy reported to have comparable results 
with surgical resection4. Radiotherapy also has a role in the 
control of incurable lung cancer, which affected two thirds of 
the 1143 total cases diagnosed in Northern Ireland in 20125.
As observed in the general population, patients who are male, 
older age, African-Caribbean background, have pre-existing 
cardiac disease or have other co-morbidities experience 
a greater risk of cardiovascular morbidity following 
thoracic irradiation6. It is difficult to precisely determine 
the direct impact of radiotherapy from other risk factors for 
cardiovascular disease in patients with lung cancer owing 
to the sizeable impact of smoking. Ischaemic heart disease 
is more common in patients with tumours of the left lung 
compared with the right, after radiation treatment6. Recently 
developed alternative methods of delivery of thoracic 
radiotherapy have achieved increased survival rates and 
reduced treatment durations for patients without increasing 
long-term toxicity7. 
Breast cancer
Given the very high local control rates seen in patients with 
early breast cancer, an increased emphasis on avoidance of 
toxicity is given. Breast cancer radiotherapy constitutes 30% 
of a radiotherapy unit’s caseload8. Adjuvant radiotherapy 
is offered to patients diagnosed with early and locally 
advanced breast cancer (over a third of patients with breast 
cancer receive radiotherapy9). However, in previous large 
overviews of breast cancer using data collected over 40 years, 
the reduced breast  cancer mortality attributable to adjuvant 
radiotherapy did not always translate into an overall survival 
gain, probably due to an increased cardiac mortality in 
patients receiving treatment to the left breast10,11. 
Major coronary events after left-sided breast irradiation have 
a bimodal peak incidence, with many patients affected in the 
4 years post-treatment, and others >20 years post-treatment10. 
It has been shown that unintended cardiac irradiation during 
left breast treatment occurs in almost one half of patients 
despite CT-based treatment plans excluding this area12. As 
seen with lung cancer, cardiotoxicity in breast radiotherapy 
is dependent upon laterality, with a cardiovascular mortality 
ratio of 1.33 (left breast versus right) for treatment delivered 
in the 1970s13. Women aged < 35 years are at greatest risk of 
radiation toxicity, with a 6.5 x lifetime risk of cardiovascular 
death compared with the general population14. Recent 
evidence suggests that for selected older patients, with low 
risk breast cancer, the cardiovascular risks of radiotherapy 
may outweigh the potential benefits15. The burden of 
cardiotoxicity in patients with breast neoplasms has decreased 
as a consequence of improvements in radiation technology 
and some investigators have found the effect of tumour 
laterality has been negligible since 199316,17. 
Other thoracic radiotherapy
Mantle radiotherapy describes the extended pattern of 
radiation fields used to target supra-diaphragmatic lymph 
node groups, often encompassing the mediastinal and hilar 
lymphatics. Hodgkin’s disease patients, for whom mantle 
radiotherapy was primarily used in the past have a higher risk 
of developing calcific valvular disorders (both stenosis and/or 
regurgitation)18, myocardial infarction, cardiomyopathy and 
pericardial disease19. As a result, the relative risk of patients 
in this group developing heart failure is 4.919. This group of 
patients are also at risk of symptomatic (usually syncope) and 
asymptomatic conduction abnormalities20. 
A recent review of the limited data on oesophageal cancer 
found a crude rate of radiation cardiotoxicity in these patients 
of 10.8%21. Adverse effects in order of increasing incidence 
were pericardial effusion, ischaemic events and heart failure. 
A recent review of pacemaker and implantable cardiac 
defibrillator safety in radiotherapy has acknowledged that 
Fig 1. A linear accelerator for EBRT
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certain energies of radiotherapy pose a risk of malfunction 
and clinical oncologists are awaiting an update in the relevant 
guidelines22.
Systemic anti-cancer therapy
Anthracyclines
Drugs such as doxorubicin and epirubicin form disruptive 
cross-links between paired DNA strands. They have an 
important role in the chemotherapy regime for many 
cancers including breast, gastrointestinal and blood. 
Cardiotoxicity due to an anthracycline is seen in 5.4% 
of breast cancer patients, and has been viewed as dose-
dependent and related to the cumulative dose given over 
time23. The increased cardiac event rate is usually observed 
many years after treatment and is related to a patient’s 
pre-existing cardiovascular risk factors24. Under the age 
of 70, anthracycline cardiotoxicity most often manifests 
as heart failure in breast cancer treatment25. Alternative 
preparations of the drug can be used to reduce the risk. 
Liposomal infusions may be less harmful than boluses and 
cardioprotective agents may be co-administered to further 
reduce the effect (e.g. angiotensin converting enzyme (ACE) 
inhibitors, beta blockers, dexrazozane) have been used26,27. 
Another anthracycline, epirubicin has been associated with 
mild rises in troponin levels unrelated to ischaemic events in 
the month following infusion28.
Trastuzumab
Trastuzumab is a monoclonal antibody directed towards the 
HER2 epidermal growth factor receptor and is licensed for 
use in metastatic breast cancer patients with over-expression 
of this receptor29. The associated type of cardiac dysfunction 
differs from that seen with classic cytotoxic drugs in that it is 
observed early (i.e. within weeks of commencing treatment), 
in a range of severities, independent of dose and it has a 
mainly reversible pattern without any ultrastructure changes30. 
In a study of 179 breast cancer patients, 44% of patients 
developed a cardiac event (defined as New York Heart 
Association (NYHA) III or IV heart failure or a reduction 
in ejection fraction) during the year of treatment, and almost 
a tenth had a second31. A total of 7% patients in this study 
had their trastuzumab discontinued, though discontinuing 
treatment did not affect the rates of a second cardiac event 
occurring. Prior or concomitant radiation therapy doesn’t 
influence trastuzumab cardiotoxicity32, but anthracycline 
therapy does33. 
Other SACTs
Intercalating agents such as cyclophosphamide employ a 
similar mechanism of action to anthracyclines (disruption 
of DNA ‘unzipping’ in replicating cancer cells) and are 
associated with early heart failure (one week post-treatment) 
and haemorrhagic myocarditis34. 
Antimetabolite drugs such as 5-fluorouracil (5-FU), have a 
number of mechanism of actions, but exert their main effect 
by triggering apoptosis in malignant cells by a process called 
a thymineless death35. These drugs may cause acute chest 
pain during or shortly after administration which occurs 
through the mechanism of coronary artery vasospasm36. 
Recognition of this is important for patients on capecitabine 
and infusional 5-FU as on-ongoing administration of those 
agents must be stopped until the symptoms have settled and 
cardiac investigations are completed. 
Platinum-based intercalating agents may also cause this 
symptom. Unlike the pattern seen in antimetabolites, the risk 
continues for many years, and cisplatin can be detected in the 
serum at 20 years37. 
Taxane drugs such as paclitaxel and docetaxel disturb the 
microtubules needed to separate original and fresh copies 
of DNA in the dividing cell. These are commonly used in 
ovarian and breast cancer treatment and have been linked 
to heart block, bradycardia and tachyarrhythmias with a 
cumulative incidence of 0.5%38. 
Hormonal treatments have not been consistently shown to 
increase the risk of cardiac events despite interfering with 
lipid metabolism23. 
Bevacizumab, an agent targeting vascular endothelial growth 
factor receptors used in colorectal cancer, has been linked 
to cardiotoxicity via hypertension and thromboembolism39. 
Sunitinib targets this receptor in renal cell carcinoma and was 
strongly associated with cardiotoxicity in one large study40. 
Over a tenth of patients experienced  cardiovascular events 
including myocardial infarction and heart failure, over a 
quarter had an asymptomatic decrease in ejection fraction of 
10% or more and almost one half of patients were diagnosed 
with hypertension following drug administration. 
DIAGNOSIS OF HEART FAILURE
Whilst oncological treatments may cause a range of adverse 
TABLE 2: 
Commonly used cardiotoxic SACT and their adverse 
cardiovascular effects
Drug / Family of 
Drugs
Cardiotoxicities
Anthracyclines Heart failure (late and irreversible)
Trastuzumab Heart failure (early and reversible)
Cyclophosphamide Heart failure (early), haemorrhagic 
myocarditis
Antimetabolites Coronary vasopasm, acute 
coronary syndromes
Platinum Acute coronary syndromes
Taxanes Heart block, bradycardia, 
tachyarrhythmia
Bevacizumab Hypertension, thromboembolism
Sunitinib, sorafenib, 
pazopanib
Hypertension, heart failure, 
myocardial infarction
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cardiovascular conditions, the commonest is heart failure. 
Heart failure is a complex syndrome in which the ability of 
the heart to maintain the circulation of blood is impaired41. 
Approximately half of patients die within 4 years42 however 
mortality rates are improving43. 
Biomarkers of cardiac injury (e.g. cardiac troponin I 
concentration) have been shown to identify patients at risk 
for anthracycline cardiotoxicity and predict a poor response 
to cardiac therapy44,45. The finding of a significantly raised 
B-type natriuretic peptide level (BNP or its precursor 
fragment NT-proBNP) provides evidence of heart failure with 
high sensitivity46. Whilst not useful in an unselected cohort 
of patients receiving SACT, NT-proBNP trends can identify 
at-risk patients treated with anthracyclines47. 
Echocardiography is an excellent tool for identifying the 
patient with heart failure. A reduction in left ventricular 
ejection fraction (LVEF) is a late finding and may occur only 
after a significant amount of myocardial damage has occurred. 
Advanced echocardiographic techniques such as global 
longitudinal strain measurement may detect left ventricular 
impairment earlier than conventional LVEF48. Deteriorations 
of 13.7% or more from baseline warrant continued increased 
clinical vigilance with fair sensitivity (88%) and specificity 
(71%)49.
CANCER THERAPEUTICS-RELATED CARDIAC 
DYSFUNCTION 
Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD) 
is defined by the European Society of Cardiology (ESC) as 
a decrease in LVEF of 10% or more, to a value less than the 
normal range50. CTRCD can further be divided into those 
who develop symptoms of overt heart failure and those who 
have an asymptomatic decline in systolic function. The ESC 
also sub-classifies systolic dysfunction by the degree of 
reversibility following clinical intervention:
• Reversible (returns to within 5% of baseline)
• Partly reversible (>10% improvement, >5% below 
baseline) 
• Irreversible (<10% improvement, >5% below baseline). 
It is felt that the most important factor is demonstration of 
reversibility. 
All patients should be treated with an ACE inhibitor/
angiotensin II receptor blocker (ARB) and a beta blocker 
licensed for heart failure. Some of these drugs have been 
assessed specifically in CTRCD patients, and may be 
preferable to others in the same drug class, as not all agents 
seem to be beneficial51. 
In patients with early evidence of left ventricular impairment 
during cancer treatment, introduction of ACE inhibitors and 
possibly beta blockers may be helpful to recover cardiac 
function, and offer cardioprotection against further cancer 
treatment if required - particularly those with a history of 
cardiac disease. Different strategies are currently employed 
in various specialist centres with Cardio-Oncology services, 
including surveillance with echocardiography and cardiac 
biomarkers, early detection and cardioprotection during 
chemotherapy or cardiotoxic targeted molecular therapies. 
Involvement of the Heart Failure Specialist Team is essential.
TRASTUZUMAB
It is important to appreciate that the majority of the 44% 
patients developing cardiotoxicity after trastuzumab had mild 
TEXT BOX 2:
Recommended actions for patients undergoing cardiotoxic anticancer therapy
BEFORE COMPLETING TREATMENT AFTER COMPLETING TREATMENT
Be aware of the cardiotoxic potential of patients’ anti-cancer treatment plan
Investigate new or changing cardiovascular symptoms
Ensure patients are aware of the potential for heart problems 
during/after cancer treatment 
Monitor weight, lipid profile, glycaemic control during 
hormonal therapies
Update the Oncologist early with relevant investigation 
results and medication changes 
Regular and relevant cardiac function testing no later than 
6 months following high-risk treatments and if normal/
asymptomatic
Approach metastatic and non-metastatic patients with 
identical monitoring
Liaise with a cardiologist if there is a suspicion of 
cardiotoxicity
TEXT BOX 1: 
Application of natriuretic peptides to CTRCD
- raised natriuretic peptide level is evidence of 
heart failure (highly sensitive)
- elevated NT-proBNP after an anthracycline 
identifies patients at risk of CTRCD
- CTRCD is not limited to high-dose regimes
- persistent elevations after 72 hrs predict progres-
sive decline in left ventricular failure
- raised levels are associated with a greater risk of 
developing trastuzumab CTRCD
Cardiotoxicity Following Cancer Treatment 7
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).
The Ulster Medical Society grants to all users on the basis of a Creative Commons Attribution-NonCommercial-ShareAlike 
4.0 International Licence the right to alter or build upon the work non-commercially, as long as the author is credited 
and the new creation is licensed under identical terms.
or no symptoms31. The implication of previous or concurrent 
anthracycline is also worth recognising - this triples the 
risk31. Whilst no study has been designed to test this link 
specifically, a recent very large population-based study 
indicates that sequential therapy (anthracycline followed 
by trastuzumab) is more dangerous (4 x hazard ratio) than 
concomitant treatment (2 x hazard ratio)52. It is postulated 
that the cumulative oxidative damage from an anthracycline is 
negatively modulated in the vulnerable by trastuzumab via its 
direct mechanism of action on the HER2 pathway and some 
data suggests that a delay in initiating trastuzumab allows the 
myocytes to recover before a “second hit”44.
New elevations in cardiac troponin I were commonly seen 
after the first cycle, resolved within 3 months with patients 
developing cardiovascular symptoms by 8 months. In the 
same study, baseline troponin elevation patterns (following 
cytotoxic chemotherapy and prior to trastuzumab) were 
consistent with the hypothesis that the conventional time to 
commence trastuzumab may be during a period of myocyte 
vulnerability52. Therefore abnormal troponin values should 
prompt clinicians to follow up symptoms actively whilst a 
Cardio-oncology opinion is awaited. There is less data about 
using BNP for diagnosis and prediction of CTRCD with 
trastuzumab, compared with anthracyclines. Exploratory 
analyses have established that NT-BNP can be raised in 
absence of impaired LVEF on echocardiogram 53, suggesting 
LVEF is not sensitive enough to detect subclinical damage 
from SACT. The Australian CATS (Cardiotoxicity of 
Adjuvant Trastuzumab) study should address this need when 
it is reported 54.
Protocols for managing trastuzumab cardiotoxicity have 
been developed55,56. In the event of a severe drop in LVEF 
or the development of clinical heart failure, cessation 
of trastuzumab is clearly indicated. For cases with mild 
subclinical dysfunction, continuation of therapy with careful 
LVEF monitoring and protective medical therapy may be 
appropriate. Figure 2 is the traffic light triage approach 
suggested by the National Cancer Research Institute55. 
The traffic light system guides clinicians when to increase 
monitoring, when to refer to Cardiology and when to 
continue/discontinue trastuzumab and ACE inhibitors. 
The clinical outcome of trastuzumab cardiotoxicity is more 
favourable than anthracyclines and in many cases, re-
challenge may be safely carried out44. In the PRADA study, 
patients randomised to cardioprotection with candesartan or 
metoprolol suffered less cardiotoxicity from trastuzumab with 
candesartan (no benefit from metoprolol observed)50. Future 
studies should seek to clarify the need for cardioprotection 
as trastuzumab becomes increasingly prescribed not only for 
breast but other tumour types. 
CONCLUSIONS
Cardiovascular disease and cancer are very common 
treatable conditions. Survival rates for cancer have 
increased significantly over the last three decades. Increased 
survivorship increases the chances of developing treatment 
related complications such as cardiovascular disease. Both 
oncologists and non-oncologists need to be aware of the 
clinical syndromes and the potential treatments available 
for cardiovascular disease related to cancer treatment. The 
development of new specialist Cardio-Oncology services 
can help oncologists, haematologists and primary care access 
specialist care for cancer patients before, during and after 
treatment with cardiotoxic therapy.
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LVSD, but the frequency of these additional tests is no more than
in the present guidance. This slightly reduced frequency of
onitoring reflects the more proactive approach to preventing
cardiac events, and increased understanding of the time course
and reversibility of trastuzumab-induced LVSD.
SYMPTOMATIC HEART FAILURE
Patients developing signs and symptoms of heart failure should
have their trastuzumab treatment interrupted, have ACE inhibitor
therapy initiated by the oncologist, and be referred to a
cardiologist. Investigation and treatment is recommended in
accordance with present guidelines (NICE, 2003; Bonow et al,
2005; Swedberg et al, 2005).
ASYMPTOMATIC DECREASE IN LVEF
For the purposes of these recommendations, an LVEF of 0.40 or
less has been taken to represent biologically important LVSD. This
is in keeping with the many studies showing that at this level of
LVEF, intervention with pharmacotherapy influences an otherwise
adverse outcome.
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Figure 1 Current recommendations for cardiac monitoring in trastuzumab-treated patients (reproduced from Suter et al, 2007; online Appendix only).
Reproduced with permission of the American Society of Clinical Oncology, from Suter et al, 2007.
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Figure 2 Traffic light system to prevent, monitor, and manage cardiac events in patients undergoing cytotoxic chemotherapy. (A) Patient assessment
during trastuzumab therapy; (B–D) indications for ACEi therapy and referral to a cardiologist before (B) and after (C) chemotherapy, and (D) during
trastuzumab therapy, when additional cardiac assessments may also be required. ACEi¼ angiotensin-converting enzyme inhibitor.
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